BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following the release of positive overall survival data from its Phase 2 clinical study involving Bria-IMT in combination with an immune checkpoint inhibitor. The treatment is aimed at patients with late-stage metastatic breast cancer. However, despite this recent […]
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for cancer treatment. sCD80 was developed originally by Suzanne Ostrand-Rosenberg from the Emeritus Faculty at UMBC. According to BriaCell Therapeutics, sCD80 was well-tolerated in animal models, and by […]
BriaCell Therapeutics has secured the fast track status from the US Food and Drug Administration (FDA) for its lead candidate — Bria-IMT for the treatment of metastatic breast cancer. The US-based clinical-stage biotech company specializes in targeted immunotherapies for cancer. Bria-IMT is a cell-based immunotherapy, which has been designed to preferentially kill tumor cells without […]